Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**2,6-Dimethoxy-1,4-benzoquinone (2,6-DMBQ)** is a synthetic and naturally occurring benzoquinone derivative found in various plants such as Rauvolfia vomitoria and Tibouchina pulchra. It is known for its antibacterial properties at physiological concentrations and has demonstrated cytotoxicity and genotoxicity at higher doses. Mechanistically it inhibits anaerobic glycolysis in cells by interfering with cellular metabolism and can induce apoptosis. It has also been studied for potential anti-platelet aggregation activity in vitro and as an anticancer agent due to its redox cycling properties[1][3][7]. However, it is also recognized as a contact allergen present in many wood species[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2,6-dimethoxy-1,4-benzoquinone.